Skip to content
Sarah L. Spitznogle

Sarah L. Spitznogle


Call Center (585) 276-3000


Residency & Fellowship

PGY2 Infectious Diseases Pharmacy Residency, The University of Texas MD Anderson Cancer Center, Houston TX 2019 - 2020

PGY1 Acute Care Pharmacy Residency, UPMC Presbyterian, Pittsburgh PA 2018 - 2019


Doctor of Pharmacy | University at Buffalo School of Pharmacy and Pharmaceutical Sciences. 2018


Journal Articles

Genetic determinants underlying the progressive phenotype of ?-lactam/?-lactamase inhibitor resistance in .

Shropshire WC, Amiji H, Bremer J, Selvaraj Anand S, Strope B, Sahasrabhojane P, Gohel M, Aitken S, Spitznogle S, Zhan X, Kim J, Greenberg DE, Shelburne SA

Microbiology spectrum.. 2023 December 1211 (6):e0222123. Epub 10/06/2023.

Significant Publications on Infectious Diseases Pharmacotherapy in 2019.

Hendrickson JA, Spitznogle SL, Gonzales-Luna AJ, Babic JT, Britt RS, Knight JM, Pham SN, McDaneld PM

Journal of pharmacy practice.. 2021 October 34 (5):800-813. Epub 09/16/2020.

An Overview of the Treatment of Less Common Non-Lactose-Fermenting Gram-Negative Bacteria.

Spencer HK, Spitznogle SL, Borjan J, Aitken SL

Pharmacotherapy.. 2020 September 40 (9):936-951. Epub 08/14/2020.

A combination of ceftaroline and daptomycin has synergistic and bactericidal activity in vitro against daptomycin nonsusceptible methicillin-resistant Staphylococcus aureus (MRSA).

Shafiq I, Bulman ZP, Spitznogle SL, Osorio JE, Reilly IS, Lesse AJ, Parameswaran GI, Mergenhagen KA, Tsuji BT

Infectious diseases.. 2017 May 49 (5):410-416. Epub 01/24/2017.